Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Svrcek

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pathology|December 3, 2003
Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray studyM Svrcek, F Jourdan, N Sebbagh, et al.
British Journal of Cancer|July 23, 2013
Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancerN Chaput, M Svrcek, A Aupérin, et al.
Clinics and Research in Hepatology and Gastroenterology|March 6, 2023
Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinomaL Mas, J Cros, M Svrcek, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|June 13, 2018
Prognostic value and characteristics of N1c colorectal cancerM Bouquot, B Creavin, N Goasguen, et al.
Clinical Genetics|April 12, 2011
Unexplained polyposis: a challenge for geneticists, pathologists and gastroenterologistsC Mongin, F Coulet, J H Lefevre, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2013
Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinomaH Vuarnesson, R M Lupinacci, O Semoun, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategyM Svrcek, A Cayre, T Samaille, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)S Watson, C de la Fouchardière, S Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2019
Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52]S Watson, C de la Fouchardière, S Kim, et al.
Journal of Crohn'S & Colitis|January 13, 2022
ECCO Position on Harmonisation of Crohn's Disease Mucosal HistopathologyF Magro, J Sabino, F Rosini, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pathology|December 3, 2003
Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray studyM Svrcek, F Jourdan, N Sebbagh, et al.
British Journal of Cancer|July 23, 2013
Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancerN Chaput, M Svrcek, A Aupérin, et al.
Clinics and Research in Hepatology and Gastroenterology|March 6, 2023
Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinomaL Mas, J Cros, M Svrcek, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|June 13, 2018
Prognostic value and characteristics of N1c colorectal cancerM Bouquot, B Creavin, N Goasguen, et al.
Clinical Genetics|April 12, 2011
Unexplained polyposis: a challenge for geneticists, pathologists and gastroenterologistsC Mongin, F Coulet, J H Lefevre, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 17, 2013
Number of examined lymph nodes and nodal status assessment in pancreaticoduodenectomy for pancreatic adenocarcinomaH Vuarnesson, R M Lupinacci, O Semoun, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategyM Svrcek, A Cayre, T Samaille, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)S Watson, C de la Fouchardière, S Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2019
Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52]S Watson, C de la Fouchardière, S Kim, et al.
Journal of Crohn'S & Colitis|January 13, 2022
ECCO Position on Harmonisation of Crohn's Disease Mucosal HistopathologyF Magro, J Sabino, F Rosini, et al.
Pageof 4